Finlay Vaccine Institute
COVID-19 vaccine: Cuba hopeful about indigenous vaccine in Phase 3 trial

In previous trials, the Soberana 02 vaccine candidate generated antibody response in about 80% of the people who were administered two doses

Cuba working on a ‘People’s Vaccine’: the US and the world should get behind it

Amid growing accusations of vaccine hoarding by global north countries and patents blocking vaccine production, researcher and filmmaker Beth Geglia writes about the importance of supporting Cuba’s vaccines which will be available to all

Cuba’s anti-COVID vaccine candidate Soberana 02 begins phase III clinical trials

In this final and decisive phase of trials, the objective is to evaluate the efficacy, safety and immunogenicity of Soberana 02. If the vaccine produces fruitful results, Cuba will become the first country in the Latin American and the Caribbean region to develop its own vaccine

Cuba is one step closer to launching its own anti-COVID vaccines

Cuba is the only country in the Latin American and the Caribbean region that is working to develop its own vaccines against COVID-19. The country has four vaccine candidates. Two of them, Soberana 02 of the Finlay Vaccine Institute (IFV) and Abdala of the Center for Genetic Engineering and Biotechnology (CIGB), will begin the third phase of clinical trials in March

Cuba’s vaccine candidate “Sovereign” begins clinical trials today

Cuba’s vaccine candidate is the first from the Latin America and the Caribbean region and marks a continuation of its pioneering work in combating COVID-19 across the world

    × To Subscribe